FDA is set for a busy June with 11 upcoming PDUFA dates, including a late-month decision that could expand the label of Ionis Pharmaceuticals’ Tryngolza olezarsen. The antisense oligonucleotide currently approved for familial chylomicronemia syndrome is being considered for expansion into severe hypertriglyceridemia, which would broaden market reach substantially. The PDUFA calendar also signals continued momentum in nucleic-acid therapeutics, as regulators weigh safety and efficacy for new indications. For biotech and pharma, the sequence of decisions in June provides a near-term window into pricing, access, and competitive positioning for lipid-lowering platforms. Ionis’ development program, which targets APOC3 via an antisense approach, is one of the highest-profile agenda items amid competing lipid therapies and evolving benefit design. Overall, the combination of a concentrated PDUFA slate and potential indication expansion means near-term outcomes could shift both pipeline expectations and commercial forecasting across the category.